Lexaria Bioscience Corp.
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-05-19
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
News release - English.pdf
News 2026-05-07
Lexaria Bioscience Releases Second Episode of Investor Video Series
News release - English.pdf
News 2026-05-01
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
News release - English.pdf
News 2026-04-29
Lexaria Bioscience Corp. Announces Extension of Material Transfer Agreement with Pharmaceutical Company
News release - English.pdf
News 2026-04-23
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
News release - English.pdf
News 2026-04-21
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
News release - English.pdf
News 2026-04-15
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
News release - English.pdf
Results 2026-04-13
Interim MD&A - English.pdf
Results 2026-04-13
Interim financial statements/report – English.pdf
News 2026-04-07
Lexaria Applauds Eli Lilly's Foundayo™ Drug Approval
News release - English.pdf
News 2026-04-01
Lexaria to Begin New Human Clinical Study in GLP-1
News release - English.pdf
News 2026-03-26
Lexaria Bioscience Corp. Announces Robust Patent Portfolio Continues to Grow with 5 New Patents Granted
News release - English.pdf
News 2026-03-24
News release - English.pdf
Results 2026-02-05
Lexaria Announces Positive Final Results from Human Pilot Study #5
News release - English.pdf
Results 2026-01-13 Financials
Interim MD&A - English.pdf
Results 2026-01-13 Financials
Interim financial statements/report – English.pdf
Results 2025-12-30
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
News release - English.pdf
Results 2025-12-23
Lexaria Bioscience Announces Primary Endpoint Successfully Achieved in Phase 1b Study GLP-1-H24-4
News release - English.pdf
News 2025-12-16
Report of exempt distribution (45-106F1).pdf
Transactions 2025-12-16 Financing
Lexaria Bioscience Corp. Announces Registered Direct Offering and Concurrent Private Placement
Material change report - English.pdf
Transactions 2025-12-16 Financing
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
News release - English.pdf
Transactions 2025-12-15 Financing
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
News release - English.pdf
News 2025-12-10
Cover letter.pdf
Results 2025-11-27 Financials
Annual report on form 10-K - English.pdf
Results 2025-11-27 Financials
Annual MD&A - English.pdf
Results 2025-11-27 Financials
Audited annual financial statements – English.pdf
News 2025-11-12
News release - English.pdf
News 2025-10-09
News release - English.pdf
News 2025-10-01
Report of exempt distribution (45-106F1).pdf
News 2025-09-29
Material change report - English.pdf
News 2025-09-29
News release - English.pdf
News 2025-09-26
News release - English.pdf
News 2025-09-25
Material change report - English.pdf
News 2025-09-19
News release - English.pdf
News 2025-08-27
News release - English.pdf
News 2025-08-14
News release - English.pdf
News 2025-08-06
News release - English.pdf
News 2025-07-28
News release - English.pdf
News 2025-07-23
News release - English.pdf
Results 2025-07-14 Financials
Interim MD&A - English.pdf
Results 2025-07-14 Financials
Interim financial statements/report – English.pdf
News 2025-06-23
News release - English.pdf
News 2025-06-12
Material change report - English.pdf
News 2025-06-11
News release - English.pdf
News 2025-06-05
News release - English.pdf